Clinical Outcomes of an Innovative Poly‐L‐Lactic Acid (LASYNPRO) in Facial Rejuvenation: Prospective, Multicenter Spanish Study
Journal of Cosmetic Dermatology · 2026
DOI: 10.1111/jocd.70753 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2026. Verfasst von Fernando Urdiales-Gálvez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Médico Miramar, Málaga, Spain. Hauptthemen laut MEDLINE: Skin Aging, Rejuvenation, Polyesters, Cosmetic Techniques. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nordberg Medical.
Abstract (Originalsprache)
Objective
To evaluate the clinical efficacy, patient satisfaction, safety profile, and biological impact of Poly‐L‐lactic acid (PLLA LASYNPRO) over 6 months.
Methods
This prospective, multicenter study included patients treated with PLLA‐LASYNPRO. The primary end‐point was the proportion of participants who achieved a reduction of at least 1 point in the Wrinkle‐Severity‐Rating‐Scale (WSRS). Secondary end‐points included the proportion of participants achieving at least a 1‐point reduction in the Midface‐Volume‐Deficit‐Scale (MFVDS), the degree of patient satisfaction assessed by the Global‐Aesthetic‐Improvement‐Scale (GAIS), treatment‐related biological and structural changes, and the incidence of adverse events (AEs).
Results
Thirty‐six female subjects were enrolled. Right‐side treatment success rates increased from 44.4% at month‐1 to 71.9% at month‐6 (Cochran's Q , p = 0.005); left‐side rates increased from 44.4% to 68.8% ( p = 0.006). MFVDS‐treated‐side success increased significantly (44.4% to 65.6%; p = 0.004). GAIS ratings of “Much Better” or “Better” were reported by 66.7% at month 1 and remained high (65.6% at month‐6). Ultrasound and elastography imaging confirmed increased tissue density, reduction of the Sub‐Epidermal‐Low‐Echogenic‐Band (SLEB), signs of neocollagenesis, and improved viscoelasticity. Serum P1CP levels rose significantly from 134.6 ± 98.9 ng/mL to a peak of 233.2 ± 163.1 ng/mL at month 2 ( p < 0.001 vs. baseline), remaining elevated through month 6 ( p = 0.012). AEs were limited to mild–moderate, self‐resolving inflammation, erythema, edema, and injection‐site discomfort; no serious AEs occurred.
Conclusion
PLLA‐LASYNPRO achieved significant, sustained improvements in facial wrinkles and volume with high patient satisfaction and biological evidence of collagen stimulation. The treatment demonstrates an excellent safety profile. Further large‐scale, randomized trials are recommended to confirm long‐term efficacy and define its role in aesthetic practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Médico Miramar, Málaga, Spain.
- Clínica ROBEGA, Madrid, Spain.
- Clínica Iratxe Díaz, Bilbao, Vizcaya, Spain.
ORCID-Profile: Fernando Urdiales-Gálvez, Paula A Benítez
Förderung
- Nordberg Medical
Zitieren
APA
Urdiales-Gálvez, F., Benítez, P. A., & Díaz, I. (2026). Clinical Outcomes of an Innovative Poly‐L‐Lactic Acid (LASYNPRO) in Facial Rejuvenation: Prospective, Multicenter Spanish Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70753
Vancouver
Urdiales-Gálvez F, Benítez PA, Díaz I. Clinical Outcomes of an Innovative Poly‐L‐Lactic Acid (LASYNPRO) in Facial Rejuvenation: Prospective, Multicenter Spanish Study. Journal of Cosmetic Dermatology. 2026. doi:10.1111/jocd.70753
BibTeX
@article{UrdialesGlvez2026,
author = {Urdiales-Gálvez, Fernando and Benítez, Paula A and Díaz, Iratxe},
title = {Clinical Outcomes of an Innovative Poly‐L‐Lactic Acid (LASYNPRO) in Facial Rejuvenation: Prospective, Multicenter Spanish Study},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
doi = {10.1111/jocd.70753}
}
EUVIMED